tirzepatide super obesity bmi 60 pharmacotherapy in older adults: a narrative review of evidence Weight regain after the withdrawal

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), as well as the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound), may contribute to this uncomfortable symptom through their effects on digestion

Orent refers to this way of doing business as "predatory marketing" in that drug manufacturers are required to recover and add to the 50 percent of people who stop using the drugs on an annual basis to ensure constant growth

Dietary copper is usually adequate, and excess copper supplementation can be harmful

We therefore propose that GLP-1(936) plays an important and previously unrecognised role as a systemic inhibitor of glucagon secretion (but not the only one)